DB:2IVA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence.


Snowflake Analysis

Mediocre balance sheet with moderate growth potential.


Similar Companies

Share Price & News

How has Indivior's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2IVA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

140.9%

2IVA

0.6%

DE Pharmaceuticals

2.2%

DE Market


1 Year Return

150.0%

2IVA

18.1%

DE Pharmaceuticals

-3.9%

DE Market

Return vs Industry: 2IVA exceeded the German Pharmaceuticals industry which returned 17.4% over the past year.

Return vs Market: 2IVA exceeded the German Market which returned -4.5% over the past year.


Shareholder returns

2IVAIndustryMarket
7 Day140.9%0.6%2.2%
30 Day132.4%0.7%8.0%
90 Day205.6%2.6%-9.6%
1 Year150.0%150.0%21.8%18.1%-2.3%-3.9%
3 Year-63.7%-63.7%28.8%14.0%-7.6%-14.8%
5 Year-56.8%-58.6%30.4%7.9%-0.3%-12.9%

Price Volatility Vs. Market

How volatile is Indivior's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Indivior undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 2IVA (€6.6) is trading below our estimate of fair value (€28.87)

Significantly Below Fair Value: 2IVA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 2IVA is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: 2IVA is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2IVA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2IVA is overvalued based on its PB Ratio (14.1x) compared to the XE Pharmaceuticals industry average (3x).


Next Steps

Future Growth

How is Indivior forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

59.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2IVA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).

Earnings vs Market: 2IVA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 2IVA's is expected to become profitable in the next 3 years.

Revenue vs Market: 2IVA's revenue (5% per year) is forecast to grow slower than the German market (5.6% per year).

High Growth Revenue: 2IVA's revenue (5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 2IVA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Indivior performed over the past 5 years?

-16.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 2IVA is currently unprofitable.

Growing Profit Margin: 2IVA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 2IVA is unprofitable, and losses have increased over the past 5 years at a rate of -16% per year.

Accelerating Growth: Unable to compare 2IVA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2IVA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7%).


Return on Equity

High ROE: 2IVA has a negative Return on Equity (-243.59%), as it is currently unprofitable.


Next Steps

Financial Health

How is Indivior's financial position?


Financial Position Analysis

Short Term Liabilities: 2IVA's short term assets ($1.2B) exceed its short term liabilities ($665.0M).

Long Term Liabilities: 2IVA's short term assets ($1.2B) exceed its long term liabilities ($808.0M).


Debt to Equity History and Analysis

Debt Level: 2IVA's debt to equity ratio (605.1%) is considered high.

Reducing Debt: 2IVA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Debt Coverage: 2IVA's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if 2IVA's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is Indivior's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 2IVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 2IVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2IVA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2IVA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 2IVA is not paying a notable dividend for the German market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2IVA's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.6yrs

Average management tenure


CEO

Shaun Thaxter

6.33yrs

Tenure

US$1,009,700

Compensation

Mr. Shaun Thaxter has been the Chief Executive Officer of Indivior PLC since 2014. Mr. Thaxter served as the President and Chief Executive Officer of Reckitt Benckiser Pharmaceuticals, Inc. since 2009. Mr. ...


CEO Compensation Analysis

Compensation vs Market: Shaun's total compensation ($USD1.01M) is about average for companies of similar size in the German market ($USD1.08M).

Compensation vs Earnings: Shaun's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Shaun Thaxter
CEO & Executive Director6.33yrsUS$1.01m0.22% $1.1m
Mark Crossley
Chief Financial & Operations Officer and Executive Director3.25yrsUS$550.80k0.047% $239.0k
Christian Heidbreder
Chief Scientific Officerno datano data0.060% $302.6k
Jason Thompson
Vice President of Investor Relationsno datano datano data
Javier Rodriguez
Chief Legal Officerno datano data0.058% $291.2k
Cynthia Cetani
Chief Integrity & Compliance Officer1.58yrsno datano data
Debby Betz
Chief Corporate Affairs & Communications Officer5.58yrsno data0.019% $95.2k
Jon Fogle
Chief Human Resources Officer5.58yrsno data0.034% $171.7k
Richard Simkin
Chief Commercial & Strategy Officerno datano data0.083% $419.5k
Frank Stier
Chief Manufacturing & Supply Officer5.58yrsno data0.023% $113.9k

5.6yrs

Average Tenure

Experienced Management: 2IVA's management team is seasoned and experienced (5.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Shaun Thaxter
CEO & Executive Director6.33yrsUS$1.01m0.22% $1.1m
Mark Crossley
Chief Financial & Operations Officer and Executive Director3.25yrsUS$550.80k0.047% $239.0k
Graham Hetherington
Independent Non-Executive Director0.50yrno data0.0068% $34.5k
Howard Pien
Independent Chairmanno datano data0.020% $100.8k
Daniel Phelan
Independent Non-Executive Director5.5yrsno data0.015% $76.1k
Tatjana May
Non-Executive & Independent Director3.25yrsno data0.0031% $15.4k
Peter James Bains
Independent Non-Executive Director0.75yrno data0.0074% $37.2k
Daniel Tassé
Senior Independent Director3.67yrsno data0.0018% $8.9k
Lorna Parker
Non-Executive Director5.5yrsno data0.0035% $17.8k
A. McLellan
Non-Executive Director5.5yrsno data0.0010% $5.2k

3.7yrs

Average Tenure

60.5yo

Average Age

Experienced Board: 2IVA's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Indivior PLC's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Indivior PLC
  • Ticker: 2IVA
  • Exchange: DB
  • Founded: 2014
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£451.547m
  • Listing Market Cap: UK£504.983m
  • Shares outstanding: 732.44m
  • Website: https://www.indivior.com

Number of Employees


Location

  • Indivior PLC
  • 10710 Midlothian Turnpike
  • North Chesterfield
  • Virginia
  • 23235
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INDVLSE (London Stock Exchange)YesOrdinary SharesGBGBPDec 2014
INDVLBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBGBPDec 2014
IZQV.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDDec 2014
INDV NBMV (Bolsa Mexicana de Valores)YesOrdinary SharesMXMXNDec 2014
INVV.YOTCPK (Pink Sheets LLC)SPON ADR EA REPR 5 ORDUSUSDDec 2014
2IVADB (Deutsche Boerse AG)SPON ADR EA REPR 5 ORDDEEURDec 2014

Biography

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company’s product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. The company has a research collaboration with Virginia Tech Carilion School of Medicine to examine long-term recovery in individuals with moderate to severe opioid use disorder that received at least one dose of study treatment during the SUBLOCADE Phase 3 clinical trials. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/25 00:01
End of Day Share Price2020/05/22 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.